Author:
Dabira Edgard Diniba,Fehr Alexandra,Beloum Nathalie,Van geertruyden Jean-Pierre,Achan Jane,Erhart Annette,Martinez-Alvarez Melisa,D’Alessandro Umberto
Abstract
AbstractControlled human malaria infection (CHMI) studies, i.e. the deliberate infection of healthy volunteers with malaria parasites to study immune response and/or test drug or vaccine efficacy, are increasingly being conducted in malaria endemic countries, including in sub-Saharan Africa. However, there have been few studies on the perceptions and acceptability of CHMI by the local communities. This qualitative study assessed the perception and acceptability of such studies in The Gambia following the first CHMI study conducted in the country in March–May 2018. Data were collected through non-participant observation, in-depth interviews and focus group discussions and analyzed using NVivo 12 software with an inductive-deductive approach. Sixty-seven participants were involved, including volunteers enrolled in the CHMI, community stakeholders and members of the Gambian Ethics Committee. Respondents expressed a positive view about CHMI. Key motivating factors for participation were the financial compensation, comprehensive health checks, and willingness to support malaria research. Risks associated with participation were considered low. Concerns raised included the frequency of bleeding and the blood volume collected.
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. World Health Organization. World Malaria Report: 20 Years of Global Progress and Challenges 238 (World Health, 2020).
2. WHO. Global Technical Strategy for Malaria 2016–2030 1–35 (World Health Organization, 2015).
3. Sauerwein, R. W., Roestenberg, M. & Moorthy, V. S. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat. Rev. Immunol. 11, 57–64 (2011).
4. Chi, P. C. et al. Understanding the benefits and burdens associated with a malaria human infection study in Kenya: Experiences of study volunteers and other stakeholders. Trials 22, 1–20 (2021).
5. Roestenberg, M., Kamerling, I. M. C. & de Visser, S. J. Controlled human infections as a tool to reduce uncertainty in clinical vaccine development. Front. Med. 5, 1–8 (2018).